In Search Of Goodwill, Several Pharmas Commit To New Corporate ‘Statement Of Purpose’
Executive Summary
The updated business principles may give pharma companies leverage, or at least talking points, as they continue to engage with the Trump administration on policies like the International Pricing Index and with US lawmakers on drug pricing legislation. J&J's Gorsky heads governing committee of multi-industry business group that revised its principles.
You may also be interested in...
Trump’s Maximum Pressure Campaign On US Drug Pricing
President Trump isn’t going to let the Democrats own the drug pricing debate heading into the 2020 elections, so biopharma companies can look forward to many more headlines like the importation announcement on 31 July. When will it end?
What’s Next For The International Pricing Index? Parsing A Strange US Senate Vote
Senate Finance drug pricing bill is moving forward, with two critical amendments defeated by 14-14 tie votes. One would have stripped the inflation penalty from the bill, which probably would have killed any bipartisan momentum. The second targeted the Medicare Part B International Pricing Index and was defeated by a truly surprising set of votes.
MedPAC Analysis Of 'Low-Value' Medicare Treatments Spotlights Acthar
The Medicare Payment Advisory Commission’s annual 2018 report to Congress features the flip side of the recent value-based rhetoric – highlighting “low-value” Medicare purchases. The drug chosen to make that argument is Mallinckrodt’s HP Acthar Gel.